The next generation of immunotherapies for lung cancers



Summary

Next-generation lung cancer immunotherapies are expanding beyond traditional checkpoint inhibitors like PD-1/PD-L1 antibodies. Scientists are exploring novel targets and approaches to overcome resistance and improve efficacy. These include therapies targeting different immune checkpoints (e.g., LAG-3, TIGIT), costimulatory molecules, and the tumor microenvironment. Adoptive cell therapies, like CAR-T cell therapy, and oncolytic viruses are also being investigated. Personalized strategies using neoantigen-based vaccines and combination therapies combining different immunotherapeutic modalities or with chemotherapy/radiation are showing promise in clinical trials, aiming to broaden patient response rates and achieve durable remissions.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!